$SSSS

Neostellar Capital Corp. (SSSS): Results of Operations and Financial Condition

Neostellar Capital Corp. (SSSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001509470 0001509470 2026-07-08 2026-07-08 0001509470 NSLR:CommonStockParValue0.01PerShareMember 2026-07-08 2026-07-08 0001509470 NSLR:Sec6.00NotesDue2026Member 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE CO

Original reporting
Published Jul 8, 2026, 9:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$SSSS
Neutral
medium confidence
Mentioned
$SSSS
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SSSSNeutralMed
01

Why it matters

The key actionable update is the estimated NAV per share range at June 30, 2026, plus a portfolio update showing new investments and exits, which can influence valuation expectations until final results in August.

02

Market read

Traders can use the NAV per share estimate range and portfolio liquidity/exits to reassess near-term valuation and risk ahead of the full August earnings release.

03

What to watch

The filing does not provide full income statement or realized/unrealized breakdown, so traders may overreact to the NAV range without waiting for audited results in August.

Relevance 7/10Novelty 6/10Timing: Filed after-hours today, ahead of the company’s August 2026 Q2 results announcement.

Background

Neostellar Capital Corp. (f/k/a SuRo Capital Corp.) issued preliminary Q2 (ended June 30, 2026) estimates via an 8-K, with a press release as Exhibit 99.1.

Company-level read

Ticker impact

$SSSSNeutralMedium confidence
Context

Neostellar (SSSS) filed an 8-K with preliminary Q2 results, estimating NAV per share between $13.25 and $13.75 as of June 30, 2026.

Expected impact

Moderate volatility possible as investors reprice the NAV range versus the prior $14.24 per share (Mar 31, 2026) and $9.18 per share (Jun 30, 2025).

Evidence & confidence

The filing provides a fresh, quantified NAV estimate and portfolio transactions/exits, but it is explicitly unaudited preliminary data with results expected later in August.

Market effects

Adds datapoints on business-development company style NAV dynamics and portfolio liquidity for the alternative credit/private equity-adjacent space.

Limited, primarily impacts US-listed BDC-style closed-end/venture investment sentiment.

Low, as the disclosure is company-specific and not a macro or cross-border policy event.

Counterpoint

The NAV estimate range could be conservative or subject to quarter-end mark adjustments; portfolio exits and liquid assets may offset interim valuation pressure.

Key entities

  • Neostellar Capital Corp.

    Filed an 8-K with preliminary Q2 results and an estimated NAV per share range as of June 30, 2026.

  • CoreWeave, Inc.

    Referenced via an SPV (CW Opportunity 2 LP) where Neostellar’s realized gain is tied to CoreWeave common shares.

  • GrabAGun Digital Holdings Inc.

    Neostellar disclosed holdings and proceeds from partial exits, with net proceeds and realized gains.

Related articles

$JNJMed

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales of $25.31B (+6.6% YoY) and adjusted EPS of $2.90, both above estimates, and raised full-year guidance to a $101.1B midpoint and $11.68 adjusted EPS. Medtronic (MDT) posted its fastest annual revenue growth in a decade, with FY26 revenue $36.4B and adjusted revenue $36.3B. Article compares post-earnings positioning and risks.

$USNAMedAI 8/10

USANA Health Sciences Q2 Earnings Call Highlights

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.

$NHIMed

National Health Investors: Q2 Earnings Snapshot

National Health Investors Inc. (NHI) reported Q2 funds from operations of $57.8 million, or $1.19 per share, and net income of $55.6 million, or $1.15 per share, with revenue of $121.3 million. The REIT expects full-year funds from operations of $4.74 to $4.79 per share, according to the company.

$SGRYMed

Surgery Partners: Q2 Earnings Snapshot

Surgery Partners Inc. (SGRY) reported a Q2 loss of $15 million, or 12 cents per share. Adjusted earnings were 10 cents per share, and revenue was $848.9 million. The company expects full-year revenue of $3.35 billion to $3.45 billion, according to its earnings release.